Eris Lifesciences Ltd.

NSE: ERIS BSE: 540596 SECTOR: Pharmaceuticals & Drugs  39k   248   30

574.20
+1.40 (0.24%)
NSE: 29 Mar 4:00 PM

Price Summary

Today's High

₹ 580.45

Today's Low

₹ 570.65

52 Week High

₹ 749.85

52 Week Low

₹ 551.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

7808.67 Cr.

Enterprise Value

7762.57 Cr.

No. of Shares

13.6 Cr.

P/E

19.68

P/B

3.66

Face Value

₹ 1

Div. Yield

1.05 %

Book Value (TTM)

₹  156.83

CASH

46.11 Cr.

DEBT

0 Cr.

Promoter Holding

52.7 %

EPS (TTM)

₹  29.18

Sales Growth

9.64%

ROE

23.92 %

ROCE

26.42%

Profit Growth

18.99 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Eris Lifesciences Ltd.

GLIMISAVE ERITEL OLMIN TENDIA RENERVE REMYLIN RABONIK TAYO LNBLOC CYBLEX ATORSAVE ROSIFLEX CREVAST RARICAP SERLIFT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.64%
3 Year10.69%
5 Year11.27%

Profit Growth

1 Year18.99%
3 Year13.49%
5 Year10.95%

ROE%

1 Year23.92%
3 Year24.04%
5 Year28.21%

ROCE %

1 Year26.42%
3 Year26.09%
5 Year27.94%

Debt/Equity

0

Price to Cash Flow

21.14

Interest Cover Ratio

151.291052114061

CFO/PAT (5 Yr. Avg.)

0.905103268589903

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 52.7 0
Sep 2022 52.29 0
Jun 2022 52.3 0
Mar 2022 52.66 0
Dec 2021 52.66 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 24.0428382690259% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.0935762750201% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 151.291052114061.
  • The Company has been maintaining an effective average operating margins of 37.7768099821856% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -109.387738174956 days.
  • Company has a healthy liquidity position with current ratio of 2.6565033408464.
  • The company has a high promoter holding of 52.7%.

 Limitations

  • The company has shown a poor revenue growth of 10.6851392498692% for the Past 3 years.
  • Tax rate is low at 9.01691899035631.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 304.63 282.14 328.76 355.37 332.01
Total Expenditure 181.85 180.52 202.57 214.32 205.62
Operating Profit 122.78 101.62 126.19 141.05 126.39
Other Income 5.84 9.05 3.37 6.15 3.48
Interest 0.77 0.98 7.23 7.49 3.14
Depreciation 13.54 15.07 14.97 15.9 16.5
Exceptional Items 0 0 0 0 0
Profit Before Tax 114.32 94.63 107.36 123.81 110.23
Tax 10.26 7.92 11.77 8.61 10.85
Profit After Tax 104.06 86.71 95.59 115.2 99.38
Adjusted EPS (Rs) 7.66 6.38 7.03 8.47 7.31

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 760.6 896.54 1020.23 1108.83 1215.73
Total Expenditure 444.67 562.77 665.28 691.36 731.68
Operating Profit 315.93 333.77 354.96 417.47 484.06
Other Income 28.22 32.5 15.49 10 28.99
Interest 10.48 22.9 1.97 0.94 3.05
Depreciation 21.79 31.59 44.88 37.64 51.46
Exceptional Items 0 0 0 0 0
Profit Before Tax 311.89 311.78 323.59 388.89 458.54
Tax 18.23 26.4 32.32 38.29 41.35
Net Profit 293.66 285.38 291.27 350.61 417.19
Adjusted EPS (Rs.) 21.36 20.75 21.45 25.82 30.69

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 13.75 13.75 13.58 13.58 13.59
Total Reserves 854.43 1142.26 1286.12 1561.89 1904.96
Borrowings 273.69 0 0 0 0
Other N/C liabilities -77.36 -114.05 -130.18 -161.82 -170.49
Current liabilities 277.88 360.47 203.06 212.42 249.79
Total Liabilities 1342.4 1402.42 1372.59 1626.08 1997.86
Assets
Net Block 489.75 483.85 600.64 584.32 642
Capital WIP 0 0.75 0 0 0
Intangible WIP 0 1.98 4.37 1.56 2.98
Investments 451.84 274.36 246.03 480.97 678.18
Loans & Advances 10.95 16 15.44 25.36 11.14
Other N/C Assets 6 5.88 2.88 42.27 0
Current Assets 383.86 619.6 503.22 491.6 663.56
Total Assets 1342.4 1402.42 1372.59 1626.08 1997.86
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 311.89 311.78 323.59 388.89 458.54
Adjustment 7.63 24.57 39.36 36.11 31.04
Changes in Assets & Liabilities -15.57 -50.18 -47.37 38.44 -37.26
Tax Paid -67.67 -69.86 -50.34 -68.04 -82.9
Operating Cash Flow 236.28 216.31 265.25 395.41 369.41
Investing Cash Flow -592.73 2.08 126.74 -347.86 -267.64
Financing Cash Flow 363.26 -220.74 -333.52 -81.13 -88.42
Net Cash Flow 6.81 -2.34 58.47 -33.58 13.36

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 52.66 52.66 52.30 52.29 52.70
amit indubhusan ba... - 39.47 - - -
amit indubhushan b... 39.58 - 39.47 39.47 39.47
himanshu jayantbha... 4.57 4.57 4.57 4.57 4.57
inderjeet singh ne... 4.32 4.32 4.32 4.32 4.32
rajendrakumar ramb... 4.32 4.32 4.32 4.32 4.32
kaushal kamleshkum... 3.25 3.25 3.25 3.25 3.25
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 47.34 47.34 47.70 47.71 47.30
rakesh shah 11.53 - 11.53 11.53 11.53
rakeshbhai bhikhab... - 11.53 - - -
bhikhalal chimanla... 7.76 8.04 8.04 8.04 7.76
emerald investment... - - - - -
motilal oswal mult... 3.86 - - 3.59 3.84
hetal rasiklal shah 3.50 3.50 3.50 3.50 3.50
aditya birla sun l... - 3.50 3.27 - -
motilal oswal most... - 2.33 3.14 - -
uti - equity fund - - - - -
sbi magnum balance... - 2.95 1.40 - -
franklin india sma... - - - - -
goldman sachs indi... 1.20 1.65 1.37 1.31 1.20
matthews india fund 1.42 - 1.02 1.42 1.42
fundsmith emerging... - - - - -
abu dhabi investme... 1.01 1.01 1.01 1.01 1.01

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Eris Lifesciences informs about analyst meet 20 Mar 2023, 12:39PM Eris Lifesciences planning to acquire nine dermatology brands from Dr Reddy's Laboratories 16 Mar 2023, 2:50PM Eris Lifesciences informs about analyst meet 15 Feb 2023, 11:58AM Eris Lifesciences reports marginal fall in Q3 consolidated net profit18 Jan 2023, 12:59PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences - Quaterly Results17 Jan 2023, 5:33PM Eris Lifesciences informs about analyst meet intimation4 Jan 2023, 12:49PM Eris Lifesciences informs about analyst meet 9 Nov 2022, 12:50PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences - Quaterly Results20 Oct 2022, 12:43PM Eris Lifesciences informs about disclosure24 Sep 2022, 4:22PM Eris Lifesciences informs about institutional investor meetings19 Sep 2022, 10:26AM Eris Lifesciences informs about investor meet3 Sep 2022, 3:27PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM Eris Lifesciences - Quaterly Results5 Aug 2022, 12:55PM Eris Lifesciences informs about disclosure19 Jul 2022, 3:05PM Eris Lifesciences informs about trading window closure27 Jun 2022, 5:18PM Eris Lifesciences informs about analyst meet16 Jun 2022, 4:55PM Eris Lifesciences informs about analyst meet13 Jun 2022, 2:45PM Eris Lifesciences informs about corporate presentation18 May 2022, 4:36PM Eris Lifesciences informs about audio recording of earnings conference call5 May 2022, 2:54PM Eris Lifesciences acquires Oaknet Healthcare4 May 2022, 11:38AM Eris Lifesciences informs about disclosure4 May 2022, 9:41AM Eris Lifesciences - Quaterly Results3 May 2022, 1:52PM Eris Lifesciences - Quaterly Results3 May 2022, 1:52PM Eris Lifesciences - Quaterly Results3 May 2022, 1:52PM Eris Lifesciences informs about analyst meet4 Apr 2022, 4:53PM Eris Lifesciences informs about transcript of analyst meet3 Feb 2022, 4:31PM Eris Lifesciences informs about conference call21 Jan 2022, 12:42PM Eris Lifesciences informs about analyst meet7 Jan 2022, 4:21PM Eris Lifesciences informs about analyst meet9 Dec 2021, 3:21PM Eris Lifesciences forms JV with MJ Biopharm to enter insulin segment4 Dec 2021, 11:27AM Eris Lifesciences informs about trading window closure3 Dec 2021, 1:02PM Eris Lifesciences informs about analyst meet26 Nov 2021, 4:42PM Eris Lifesciences informs about analyst meet18 Nov 2021, 2:56PM Eris Lifesciences informs about board meeting22 Oct 2021, 12:23PM Eris Lifesciences informs about analyst meet21 Oct 2021, 2:12PM Eris Lifesciences informs about analyst meet 26 Aug 2021, 5:00PM Eris Lifesciences informs analyst meet25 Aug 2021, 11:58AM Eris Lifesciences informs about analyst meet20 Aug 2021, 12:23PM Eris Lifesciences informs about analyst meet19 Aug 2021, 2:52PM Eris Lifesciences informs about board meeting to consider interim dividend26 Jul 2021, 3:52PM Eris Lifesciences informs about board meeting21 Jul 2021, 12:00PM Eris Lifesciences informs about analyst meet6 Jul 2021, 2:14PM Eris Lifesciences informs about analyst meet24 Jun 2021, 3:25PM Eris Lifesciences informs about analyst meet21 Jun 2021, 4:22PM Eris Lifesciences informs about analyst meet 15 Jun 2021, 2:36PM

Eris Lifesciences Stock Price Analysis and Quick Research Report. Is Eris Lifesciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Eris Lifesciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 369.412 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Eris Lifesciences has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Eris Lifesciences , the EPS growth was 18.8610266638267 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Eris Lifesciences has OPM of 39.81599532791 % which is a good sign for profitability.
     
  • ROE: Eris Lifesciences have a healthy ROE of 23.9205377981273 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Eris Lifesciences

X